• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Rationale for bipolar androgen therapy (BAT) for metastatic prostate cancer.转移性前列腺癌双极雄激素疗法（BAT）的理论依据。
Cell Cycle. 2017 Sep 17;16(18):1639-1640. doi: 10.1080/15384101.2017.1360645. Epub 2017 Aug 18.
2
Adaptive auto-regulation of androgen receptor provides a paradigm shifting rationale for bipolar androgen therapy (BAT) for castrate resistant human prostate cancer.雄激素受体的适应性自动调节为去势抵抗性前列腺癌的双相雄激素治疗 (BAT) 提供了一个具有范式转移意义的基本原理。
Prostate. 2012 Oct 1;72(14):1491-505. doi: 10.1002/pros.22504. Epub 2012 Mar 6.
3
Bipolar androgen therapy in prostate cancer: Current evidences and future perspectives.双相雄激素治疗前列腺癌：当前证据和未来展望。
Crit Rev Oncol Hematol. 2020 Aug;152:102994. doi: 10.1016/j.critrevonc.2020.102994. Epub 2020 May 24.
4
Bipolar androgen therapy: the rationale for rapid cycling of supraphysiologic androgen/ablation in men with castration resistant prostate cancer.双相雄激素治疗：在去势抵抗性前列腺癌男性中进行超生理雄激素/消融快速循环的基本原理。
Prostate. 2010 Oct 1;70(14):1600-7. doi: 10.1002/pros.21196.
5
Bipolar Androgen Therapy for Men With Androgen Ablation Naïve Prostate Cancer: Results From the Phase II BATMAN Study.双相雄激素疗法用于初治雄激素剥夺的前列腺癌男性患者：II期蝙蝠侠研究结果
Prostate. 2016 Sep;76(13):1218-26. doi: 10.1002/pros.23209. Epub 2016 Jun 24.
6
Bipolar androgen therapy in the treatment of prostate cancer.双相雄激素疗法治疗前列腺癌
Clin Adv Hematol Oncol. 2018 Jun;16(6):408-411.
7
Intra-prostatic androgen levels during various androgen-blockade regimens.不同雄激素阻断方案下的前列腺内雄激素水平。
Best Pract Res Clin Endocrinol Metab. 2008 Apr;22(2):229-41. doi: 10.1016/j.beem.2008.01.002.
8
Prolonging survival in metastatic prostate cancer: the case for adrenal androgens--overview and summary of therapeutic controversies in prostatic cancer.
J Clin Endocrinol Metab. 1995 Apr;80(4):1074-8. doi: 10.1210/jcem.80.4.7714070.
9
Overview of enzyme inhibitors and anti-androgens in prostatic cancer.
J Androl. 1991 Nov-Dec;12(6):364-71.
10
Advantages of total androgen blockade in the treatment of advanced prostate cancer.全雄激素阻断在晚期前列腺癌治疗中的优势。
Semin Oncol. 1988 Apr;15(2 Suppl 1):53-61.

引用本文的文献

1
Bipolar Androgen Therapy: When Excess Fuel Extinguishes the Fire.双相雄激素疗法：当过量燃料扑灭火焰时。
Biomedicines. 2023 Jul 24;11(7):2084. doi: 10.3390/biomedicines11072084.
2
ORC6, a novel prognostic biomarker, correlates with T regulatory cell infiltration in prostate adenocarcinoma: a pan-cancer analysis.ORC6，一种新的预后生物标志物，与前列腺腺癌中的 T 调节细胞浸润相关：泛癌分析。
BMC Cancer. 2023 Mar 29;23(1):285. doi: 10.1186/s12885-023-10763-z.
3
Experience of bipolar androgen therapy (BAT) in Argentinian oncology centres.阿根廷肿瘤中心的双相雄激素疗法（BAT）经验。
Ecancermedicalscience. 2022 Dec 2;16:1480. doi: 10.3332/ecancer.2022.1480. eCollection 2022.
4
Maintenance of androgen deprivation therapy or testosterone supplementation in the management of castration-resistant prostate cancer: that is the question.雄激素剥夺治疗或睾酮补充治疗在去势抵抗性前列腺癌治疗中的维持：这就是问题所在。
Endocrine. 2022 Dec;78(3):441-445. doi: 10.1007/s12020-022-03166-w. Epub 2022 Aug 20.
5
The androgen receptor-lncRNASAT1-AKT-p15 axis mediates androgen-induced cellular senescence in prostate cancer cells.雄激素受体-长链非编码 RNA SAT1-AKT-p15 轴介导雄激素诱导的前列腺癌细胞衰老。
Oncogene. 2022 Feb;41(7):943-959. doi: 10.1038/s41388-021-02060-5. Epub 2021 Oct 19.
6
Titration of Androgen Signaling: How Basic Studies Have Informed Clinical Trials Using High-Dose Testosterone Therapy in Castrate-Resistant Prostate Cancer.雄激素信号滴定：基础研究如何为去势抵抗性前列腺癌高剂量睾酮治疗的临床试验提供信息。
Life (Basel). 2021 Aug 27;11(9):884. doi: 10.3390/life11090884.
7
Phenotypic characterization of two novel cell line models of castration-resistant prostate cancer.雄激素非依赖性前列腺癌细胞系模型的表型特征分析。
Prostate. 2021 Nov;81(15):1159-1171. doi: 10.1002/pros.24210. Epub 2021 Aug 16.
8
Mechanisms of Androgen Receptor Agonist- and Antagonist-Mediated Cellular Senescence in Prostate Cancer.雄激素受体激动剂和拮抗剂介导前列腺癌细胞衰老的机制
Cancers (Basel). 2020 Jul 8;12(7):1833. doi: 10.3390/cancers12071833.
9
Prostate cancer research: The next generation; report from the 2019 Coffey-Holden Prostate Cancer Academy Meeting.前列腺癌研究：下一代；2019 年科菲-霍尔顿前列腺癌学会会议报告。
Prostate. 2020 Feb;80(2):113-132. doi: 10.1002/pros.23934. Epub 2019 Dec 11.
10
Resolving the Coffey Paradox: what does the androgen receptor do in normal vs. malignant prostate epithelial cells?解决科菲悖论：雄激素受体在正常与恶性前列腺上皮细胞中发挥什么作用？
Am J Clin Exp Urol. 2018 Apr 1;6(2):55-61. eCollection 2018.

本文引用的文献

1
Androgen Deprivation Followed by Acute Androgen Stimulation Selectively Sensitizes AR-Positive Prostate Cancer Cells to Ionizing Radiation.雄激素剥夺后急性雄激素刺激可选择性地使雄激素受体阳性前列腺癌细胞对电离辐射敏感。
Clin Cancer Res. 2016 Jul 1;22(13):3310-3319. doi: 10.1158/1078-0432.CCR-15-1147. Epub 2016 Feb 1.
2
Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study.双极雄激素疗法对无症状去势抵抗性前列腺癌男性患者的疗效：一项试点临床研究的结果
Sci Transl Med. 2015 Jan 7;7(269):269ra2. doi: 10.1126/scitranslmed.3010563.
3
Adaptive auto-regulation of androgen receptor provides a paradigm shifting rationale for bipolar androgen therapy (BAT) for castrate resistant human prostate cancer.雄激素受体的适应性自动调节为去势抵抗性前列腺癌的双相雄激素治疗 (BAT) 提供了一个具有范式转移意义的基本原理。
Prostate. 2012 Oct 1;72(14):1491-505. doi: 10.1002/pros.22504. Epub 2012 Mar 6.
4
Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1.雄激素受体基因在前列腺癌中的表达被雄激素受体直接抑制，通过募集赖氨酸特异性去甲基化酶 1。
Cancer Cell. 2011 Oct 18;20(4):457-71. doi: 10.1016/j.ccr.2011.09.001.
5
DNA licensing as a novel androgen receptor mediated therapeutic target for prostate cancer.DNA许可作为一种新型的雄激素受体介导的前列腺癌治疗靶点。
Endocr Relat Cancer. 2009 Jun;16(2):325-32. doi: 10.1677/ERC-08-0205. Epub 2009 Feb 24.
6
Stabilizing androgen receptor in mitosis inhibits prostate cancer proliferation.在有丝分裂中稳定雄激素受体可抑制前列腺癌增殖。
Cell Cycle. 2007 Mar 15;6(6):647-51. doi: 10.4161/cc.6.6.4028. Epub 2007 Mar 21.
7
Androgen receptor as a licensing factor for DNA replication in androgen-sensitive prostate cancer cells.雄激素受体作为雄激素敏感性前列腺癌细胞中DNA复制的许可因子。
Proc Natl Acad Sci U S A. 2006 Oct 10;103(41):15085-90. doi: 10.1073/pnas.0603057103. Epub 2006 Oct 2.

Rationale for bipolar androgen therapy (BAT) for metastatic prostate cancer.

作者信息

Isaacs John T, Brennen W Nathaniel, Denmeade Samuel R

机构信息

a The Prostate Cancer Program, The Department of Oncology at the Sidney Kimmel Comprehensive Cancer Center and Brady Urological Institute, The Department of Urology , The Johns Hopkins School of Medicine , Baltimore , MD , USA.

出版信息

Cell Cycle. 2017 Sep 17;16(18):1639-1640. doi: 10.1080/15384101.2017.1360645. Epub 2017 Aug 18.

DOI:10.1080/15384101.2017.1360645
PMID:28820291
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5602292/
Abstract
摘要